Skip to main content.

                                          

                                                            INNOVATIVE SOLUTIONS ADVANCING TREATMENT OF HUMAN DISEASES

Technology

Targeted Cell Therapies novel delivery technology has the potential to eliminate the need for either viral and lipid vectors, or costly and difficult to manufacture injectables in disease treatment.  Our focus is on turning known injectable therapeutics into easily ingestible drugs that can be taken in an outpatient setting, and that are typically of lower cost with greater patient compliance and reduced adverse side-effects.                                                                                                                                                                                                   Targeted Cell Therapies technology permits the oral delivery of large molecules, avoiding the usual need for injection. The Company’s approach uses yeast derived glucan particles (GP) containing nanoplexed nucleic acid (DNA or RNA) payloads that encode for therapeutic molecules. Following oral administration, the GPs and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or other pathology, the GP payloads are processed by cellular machinery and produce active therapeutics.